Literature DB >> 15215148

In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.

Laurel S Almer1, Jennifer B Hoffrage, Erika L Keller, Robert K Flamm, Virginia D Shortridge.   

Abstract

In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15215148      PMCID： PMC434201          DOI： 10.1128/AAC.48.7.2771-2777.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

Authors:  G V Doern; K P Heilmann; H K Huynh; P R Rhomberg; S L Coffman; A B Brueggemann
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

Authors:  Clyde Thornsberry; Daniel F Sahm; Laurie J Kelly; Ian A Critchley; Mark E Jones; Alan T Evangelista; James A Karlowsky
Journal:  Clin Infect Dis       Date:  2002-03-01       Impact factor: 9.079

3.  Comparative in vitro activity of gemifloxacin.

Authors:  A King; J May; G French; I Phillips
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

4.  Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.

Authors:  J M Blondeau; R Laskowski; J Bjarnason; C Stewart
Journal:  Int J Antimicrob Agents       Date:  2000-02       Impact factor: 5.283

Review 5.  In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

Authors:  R N Jones; M A Pfaller
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

6.  Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999.

Authors:  J A Karlowsky; M E Jones; C Thornsberry; I Critchley; L J Kelly; D F Sahm
Journal:  Int J Antimicrob Agents       Date:  2001-08       Impact factor: 5.283

7.  Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis.

Authors:  K Gupta; D F Sahm; D Mayfield; W E Stamm
Journal:  Clin Infect Dis       Date:  2001-06-05       Impact factor: 9.079

8.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Laurel S Almer; Virginia D Shortridge; Angela M Nilius; Jill M Beyer; Niru B Soni; Mai H Bui; Gregory G Stone; Robert K Flamm
Journal:  Diagn Microbiol Infect Dis       Date:  2002-07       Impact factor: 2.803

10.  Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).

Authors:  M A Pfaller; R N Jones; G V Doern; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more
  22 in total

1.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 3.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Alexandra Adler; Saira Chaudhry; Tamara Goldberg
Journal:  P T       Date:  2018-11

6.  Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Brian J Morrow; John L Melton; Robert K Flamm; Alfred M Barron; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

7.  Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates.

Authors:  Wafi Siala; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Marie Hallin; Olivier Denis; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

8.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors:  Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

10.  In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.